Virtual | Virtual
Event Title
FDA/CDER and AASLD 2021 DILI Conference XVIII
April 20 - 22, 2021
- Date:
- April 20 - 22, 2021
- Day1:
- Tue, Apr 20
- Day2:
- Thu, Apr 22
FDA/CDER and AASLD 2021 DILI Conference XVIII.
Date: April 20-22, 2021,
Time: 9:00 AM – 4:00 PM.
This is a virtual / online program.
Goals and Objectives:
The purpose of this scientific conference is to provide a forum for open discussion between industry, government and academia of ways in which to predict, measure, evaluate and act upon liver injury and dysfunction caused by drugs in clinical trials and in post-market treatment populations; to ensure the leading experts in industry, academia and the FDA have an opportunity to discuss current and evolving practices in the analysis of hepatotoxicity and the performance of adequate liver safety studies.
Who Should Attend:
The goal audience for the conference is scientists in government, industry and academia interested in hepatotoxicity related to pharmaceutical drugs, biological agents and dietary supplements from a clinical, non-clinical and post-marketing perspective.
Contact Information
FDA: Cheryl Campbell: Cheryl.campbell@fda.hhs.gov
AASLD: Matthew D’Uva, FASAE CAE: mduva@aasld.org
AASLD: Anne Wrobel, Project Manager: awrobel@aasld.org